Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 01/06/2024 am IST			5-day change	1st Jan Change
1.714 ^USD	-0.06%		-12.10%	-45.06%

31/05	European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	MT
24/05	European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	MT

Akari Therapeutics, plc Announces Management Changes, with Effect from May 08, 2018

May 11, 2018 at 05:30 pm IST

On May 8, 2018, Dr. David Horn Solomon, resigned as Chief Executive Officer and as a member of the Board of Directors of Akari Therapeutics, Plc, effective immediately. Also effective on May 8, 2018, the Board appointed Clive Richardson to serve as the company's interim CEO. Mr. Richardson has served on the company's Board and as the company's COO for over two years.

The company is actively seeking a full-time CEO.

Latest news about Akari Therapeutics, Plc

European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	24/05	MT
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
Akari Therapeutics, Plc announced that it has received $0.5 million in funding	16/05	CI
Akari Therapeutics, Plc Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
Akari Therapeutics, plc Announces the Resignation of Rachelle Jacques from the Board of Directors	08/05	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	02/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
Akari Therapeutics, Plc Announces CEO Changes	01/05	CI
Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc	01/05	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	29/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	24/04	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	23/04	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	15/04	MT
ADRs End Lower, Leju Holdings Ltd. Declines 72%	13/04	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	12/04	MT
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	12/04	DJ

Chart Akari Therapeutics, Plc

Duration

Period

More charts

Company Profile

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AKARI THERAPEUTICS, PLC	-45.06%	1.36Cr
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs